Tirzepatide claims 41% of new GLP-1 starts in 12 months; semaglutide's CV outcome label and IRA negotiation exposure reshape a $22B US market.
The US Type 2 Diabetes market spans GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, and insulin, with an estimated 38.4 million US adults affected and total drug spend exceeding $22 billion in 2023. Tirzepatide (Mounjaro/Zepbound, Eli Lilly) achieved 41% of new GLP-1 prescriptions within 12 months of launch, driven by superior A1c reduction (2.0–2.3% at max dose) and 15–22% weight loss data from SURPASS trials.
Semaglutide's SELECT cardiovascular outcome trial (demonstrating 20% MACE reduction in overweight and obese adults without Type 2 Diabetes) is reshaping payer access policies beyond glycaemic control. Major commercial payers are constructing new step-edit pathways that require SGLT2 trial before GLP-1 access in some populations. IRA Medicare negotiation targets SGLT2 inhibitors (empagliflozin, dapagliflozin) for price reduction from 2026, creating downstream pricing pressure across the class.
Key approved Type 2 Diabetes agents — United States, 2024
| Drug (Brand / INN) | Class | Company | US Approval | Key Outcome Data | Payer Routing |
|---|---|---|---|---|---|
| Ozempic / Wegovy (semaglutide) | GLP-1 RA SC | Novo Nordisk | Dec 2017 (T2D) | SELECT: 20% MACE reduction; SUSTAIN: A1c −1.5% | Part D; preferred tier; CV label driving formulary priority |
| Mounjaro / Zepbound (tirzepatide) | GIP/GLP-1 RA SC | Eli Lilly | May 2022 (T2D) | SURPASS-2: A1c −2.3% vs sema −1.86%; weight −13kg | Part D; prior SGLT2 step-edit forming at some payers |
| Jardiance (empagliflozin) | SGLT2 inhibitor oral | BI / Lilly | Aug 2014 | EMPA-REG: 38% CV death reduction; HF hospitalisation −35% | Part D; IRA negotiation eligible 2026 |
| Farxiga (dapagliflozin) | SGLT2 inhibitor oral | AstraZeneca | Jan 2014 | DECLARE-TIMI: HHF reduction; CKD label expansion | Part D; IRA negotiation eligible 2026 |
| Victoza / Saxenda (liraglutide) | GLP-1 RA SC | Novo Nordisk | Jan 2010 (T2D) | LEADER: 13% MACE reduction; biosimilar entry pending | Part D; declining share vs tirzepatide/sema |
Sources: FDA Drugs@FDA (approval dates); NEJM SURPASS-2 (PMID 34170647); NEJM SELECT (PMID 37952131); NEJM EMPA-REG (PMID 26378978); NEJM DECLARE-TIMI 58 (PMID 30415602); IQVIA prescription data 2023.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • Formulary tier placement for tirzepatide (Mounjaro) vs semaglutide (Ozempic/Wegovy) at major commercial payers • Step-edit requirements: SGLT2 prior failure criteria by payer and plan type • Prior auth criteria comparing A1c threshold, BMI requirements, and CV risk stratification • Medicare Part D formulary evolution post-SELECT outcome label for semaglutide
Delivers
- • IRA negotiation timeline and eligibility criteria for empagliflozin (Jardiance) and dapagliflozin (Farxiga) • Projected price reduction range and Part D formulary impact by 2026 • SGLT2 class response: patent expiry map and authorised generic timelines • Downstream impact on GLP-1 step-edit requirements as SGLT2 prices fall
Delivers
- • Phase 3 readout timelines: orforglipron (Lilly oral GLP-1), retatrutide (triple agonist), CagriSema (cagrilintide + sema) • Mechanism differentiation and expected label scope vs current GLP-1 and GIP/GLP-1 agents • Commercial launch scenario: oral GLP-1 impact on injectable market share • Payer access scenarios for oral route vs injectable step-edit policies
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- The US Type 2 Diabetes market spans 38.4 million adults and $22 billion in 2023 drug spend across five classes.
- Why tirzepatide's dual GIP/GLP-1 mechanism captured 41% of new GLP-1 prescriptions within 12 months of its 2022 launch.
- SURPASS-2 data show tirzepatide reducing A1c by 2.3% versus semaglutide's 1.86%, with roughly 13kg of weight loss.
- Why semaglutide's SELECT trial, showing a 20% MACE reduction, is reshaping payer access policy beyond glycaemic control alone.
- Jardiance's EMPA-REG trial found a 38% cardiovascular death reduction and a 35% cut in heart-failure hospitalisation.
- Why both empagliflozin and dapagliflozin become eligible for IRA Medicare price negotiation starting in 2026.
- Major commercial payers including UHC, CVS/Aetna, and Cigna are building step-edit pathways requiring SGLT2 failure before GLP-1 access.
- Why semaglutide's cardiovascular outcome label is driving new Part D preferred-tier placement ahead of pure glycaemic competitors.
- How IRA Medicare negotiation targeting empagliflozin and dapagliflozin from 2026 creates downstream pricing pressure across the SGLT2 class.
- Why GLP-1 agents tirzepatide and semaglutide sit outside the current IRA negotiation list while the SGLT2 class absorbs price cuts.
- Why orforglipron, retatrutide, and CagriSema threaten to displace tirzepatide and semaglutide in Type 2 Diabetes by 2027.
- How Lilly's oral GLP-1 candidate orforglipron could reshape the market by displacing injectable step-edit policies with a pill.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries. No secondary summaries, market research reports, or unverified estimates are used. Findings are independently verified before inclusion.
US Type 2 Diabetes Competitive Intelligence sources: FDA Drugs@FDA (approval dates and labels), primary cardiovascular outcome trial publications (NEJM), ClinicalTrials.gov registrations, major commercial payer PA policy documents (UHC, CVS/Aetna, Cigna), CMS IRA negotiation schedule, and IQVIA prescription data.
- Drug approval dates and label indications verified against FDA Drugs@FDA database
- Cardiovascular outcome trial results verified against primary NEJM publications (SELECT, EMPA-REG, SURPASS-2, LEADER)
- PA and step-edit criteria verified against current UHC, CVS/Aetna, and Cigna coverage policy documents
- IRA Medicare negotiation timeline and eligibility verified against CMS published negotiation schedule 2024
Frequently asked questions
Commission this brief
AXLRx delivers US Type 2 Diabetes competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.